Abstract
The MCI construct aims to investigate the grey area existing between normal aging and dementia, in order to identify in the preclinical stage patients at risk of developing dementia. The construct of the MCI has been proposed by taking the neuropathological staging of the Alzheimers disease (AD) as reference and providing an explicit set of identifying criteria, but it has raised two main problems: (a) the variability of estimates concerning the actual rate of conversion from MCI to dementia, and (b) the number of subjects who return to normality. These problems stem in part from the operational difficulties met by the MCI identifying criteria concerned with: the memory tests used, the cut-off adopted to identify patients with an ‘objective’ memory disorder, the assessment of subjective memory disorders, and the integrity of daily living activities. After a short discussion of these operational difficulties, I will pass to shortly survey the laboratory data providing additional predictive value for the conversion of MCI to dementia (ApoE4, CSF biomarkers, Neuroimaging data, and Vascular risk factors) and some recent attempts to identify pre-MCI patients, with a purely subjective cognitive impairment. I will conclude my review by asking if we have a single MCI or a family of MCI constructs, each of whom could play a preferential role in specific clinical contexts.
Keywords: Conversion to dementia, return to normality, delayed recall, cut-off points, subjective memory disorders, daily living activities, subjective cognitive impairment
Current Alzheimer Research
Title: Origins, Controversies and Recent Developments of the MCI Construct
Volume: 7 Issue: 3
Author(s): G. Gainotti
Affiliation:
Keywords: Conversion to dementia, return to normality, delayed recall, cut-off points, subjective memory disorders, daily living activities, subjective cognitive impairment
Abstract: The MCI construct aims to investigate the grey area existing between normal aging and dementia, in order to identify in the preclinical stage patients at risk of developing dementia. The construct of the MCI has been proposed by taking the neuropathological staging of the Alzheimers disease (AD) as reference and providing an explicit set of identifying criteria, but it has raised two main problems: (a) the variability of estimates concerning the actual rate of conversion from MCI to dementia, and (b) the number of subjects who return to normality. These problems stem in part from the operational difficulties met by the MCI identifying criteria concerned with: the memory tests used, the cut-off adopted to identify patients with an ‘objective’ memory disorder, the assessment of subjective memory disorders, and the integrity of daily living activities. After a short discussion of these operational difficulties, I will pass to shortly survey the laboratory data providing additional predictive value for the conversion of MCI to dementia (ApoE4, CSF biomarkers, Neuroimaging data, and Vascular risk factors) and some recent attempts to identify pre-MCI patients, with a purely subjective cognitive impairment. I will conclude my review by asking if we have a single MCI or a family of MCI constructs, each of whom could play a preferential role in specific clinical contexts.
Export Options
About this article
Cite this article as:
Gainotti G., Origins, Controversies and Recent Developments of the MCI Construct, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050858
DOI https://dx.doi.org/10.2174/156720510791050858 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry A New Decision Tree Combining Abeta 1-42 and p-Tau Levels in Alzheimer's Diagnosis
Current Alzheimer Research Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine Effect of Diabetes on The Blood Brain Barrier
Current Pharmaceutical Design Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Design, Synthesis and Molecular Docking Studies of New Potential Piperazine Derivatives as Cognition Enhancers
Central Nervous System Agents in Medicinal Chemistry Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation
Protein & Peptide Letters Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease
Current Alzheimer Research